Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3437943 SAD in healthy subjects
NCT03841630Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2019
- Primary completion
- Jul 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing Retatrutide with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Day 43. Started Mar 2019; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03841630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841630.